Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.54
-3.65 (-1.61%)
AAPL  274.11
-4.17 (-1.50%)
AMD  207.58
-3.20 (-1.52%)
BAC  55.33
+0.19 (0.34%)
GOOG  309.32
-1.20 (-0.39%)
META  647.51
+3.28 (0.51%)
MSFT  474.82
-3.71 (-0.78%)
NVDA  176.29
+1.27 (0.73%)
ORCL  184.92
-5.05 (-2.66%)
TSLA  475.31
+16.35 (3.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.